SPIRIT V: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions

Trial Profile

SPIRIT V: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms SPIRIT-V-Registry
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 13 Oct 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 13 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 May 2009 Results have been presented at the 2009 EuroPCR conference according to an Abbott Laboratories media release; results were also reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top